• 대한본초학회지
• /
• 제35권5호
• /
• pp.13-21
• /
• 2020

Objective : The genus Glycyrrhiza has been used in food and traditional herbal medicine. Many experimental studies reported that Glycyrrhiza species possess several pharmacological properties. Glycyrrhiza new varieties WONGAM and SINWONGAM have been developed by Korea Rural Development Administration doing research for registration on Ministry of Food and Drug Safety. During the evaluations about pharmacological effect of Glycyrrhiza new varieties WONGAM and SINWONGAM, we focused the anti-allergic effect in this study. Methods : We investigated the anti-allergic effect of WONGAM and SINWONGAM compared with Glycyrrhiza uralensis Fischer and G. glabra L. using anti-dinitrophenyl-immunoglobulin E (IgE)/human serum albumin-stimulated RBL-2H3 cells, phorbol 12-myristate 13-acetate plus calcium ionophore A23187-stimulated HMC-1 cells and compound 48/80-induced anaphylaxis mice model. We analyzed the effect on the expression of various cytokines, and IgE from mast cells and the underlying molecular mechanisms of WONGAM and SINWONGAM in presented models. Results : WONGAM and SINWONGAM showed the inhibitory effect on the histamine release from rat peritoneal mast cells or human mast cells without cytotoxicity. WONGAM and SINWONGAM blocked anaphylactic shock and decreased the IgE production. Furthermore, WONGAM and SINWONGAM inhibited the productions of TNF-α and IL-6 in compound 48/80-induced anaphylaxis mice model. Conclusion : These results indicated that WONGAM and SINWONGAM would have protect effect on allergic responses through the inhibition of allergic mediators and pro-inflammatory cytokines. This study may facilitate the development on Glycyrrhiza new varieties for allergy.

• Biomolecules & Therapeutics
• /
• 제23권1호
• /
• pp.45-52
• /
• 2015

To explore the anti-allergic and anti-inflammatory effects of extracts of Petasites genus, we studied the effects of s-petasin, a major sesquiterpene from Petasites formosanus (a butterbur species) on asthma and peritonitis models. In an ovalbumin-induced mouse asthma model, s-petasin significantly inhibited the accumulations of eosinophils, macrophages, and lymphocytes in bronchoalveolar fluids. S-petasin inhibited the antigen-induced degranulation of ${\beta}$-hexosamidase but did not inhibit intracellular $Ca^{2+}$ increase in RBL-2H3 mast cells. S-petasin inhibited the LPS induction of iNOS at the RNA and protein levels in mouse peritoneal macrophages. Furthermore, s-petasin inhibited the production of NO (the product of iNOS) in a concentration-dependent manner in the macrophages. Furthermore, in an LPS-induced mouse model of peritonitis, s-petasin significantly inhibited the accumulation of polymorpho nuclear and mononuclear leukocytes in peritoneal cavity. This study shows that s-petasin in Petasites genus has therapeutic effects on allergic and inflammatory diseases, such as, asthma and peritonitis through degranulation inhibition in mast cells, suppression of iNOS induction and production of NO in macrophages, and suppression of inflammatory cell accumulation.

• 대한임상검사과학회지
• /
• 제50권1호
• /
• pp.37-43
• /
• 2018

본 연구는 전라도 장성지역의 편백나무 잎 추출물을 사용하여 in vitro에서 항염증 및 항알레르기 효과를 보고자 연구를 진행하였다. 편백나무 잎 추출물은 $50^{\circ}C$에서 감압 건조하여 실험에 사용하였으며, 총 폴리페놀 함량을 측정한 결과 $25.89{\pm}0.31mg\;GAE/g$로 나타났다. 설정된 GC-MS 분석법으로 편백나무잎 추출물의 6종 성분에 대한 함량 분석을 실시한 결과, ${\alpha}-Terpinene$ 3.03 mg/g, ${\alpha}-Terpineol$ 9.48 mg/g, limonene 5.96 mg/g, borneol 59.78 mg/g, myrcene 4.85 mg/g, sabinene 11.31 mg/g로 borneol이 가장 많은 것으로 나타났다. 편백나무 잎 추출물의 항산화 활성을 측정한 결과, $H_2O_2$와 $ABTS^+$ 라디칼에 대한 추출물의 $RC_{50}$이 각각 $5.47{\pm}0.13mg/mL$와 $4.00{\pm}0.01mg/mL$로 나타났다. 또한 마우스 유래의 대식세포주인 RAW 264.7 세포에서 LPS 100 ng/mL을 처리를 통한 염증유도 군에서 주요 인자인 NO 생성이 $28{\pm}0.38{\mu}M$까지 증가하였으나 편백나무 잎 추출물 $150{\mu}g/mL$ 처리 농도에서 $IC_{50}$ 으로 감소할 것으로 추정되므로, 편백나무 잎 추출물이 항염증 작용이 있음을 시사한다. 알레르기 주요 인자인 ${\beta}-hexosaminidase$의 경우 처리한 편백나무 잎 추출물의 농도 의존적으로 감소되어 항알레르기 효능이 있음을 알 수 있었으며, 인간 유래 섬유아세포인 CCD-986sk 세포에 대해 편백나무 잎 추출물의 농도 $100{\sim}800{\mu}g/mL$ 범위에서 세포독성을 전혀 보이지 않았다. 따라서 편백나무 잎 추출물이 향후 기능성 화장품, 연고 등의 산업화에 광범위하게 이용될 수 있을 것으로 사료된다.

• Biomolecules & Therapeutics
• /
• 제28권5호
• /
• pp.456-464
• /
• 2020

Mast cells (MCs) are systemically distributed and secrete several allergic mediators such as histamine and leukotrienes to cause type I hypersensitivity. Dasatinib is a type of anti-cancer agent and it has also been reported to inhibit human basophils. However, dasatinib has not been reported for its inhibitory effects on MCs or type I hypersensitivity in mice. In this study, we examined the inhibitory effect of dasatinib on MCs and MC-mediated allergic response in vitro and in vivo. In vitro, dasatinib inhibited the degranulation of MCs by antigen stimulation in a dose-dependent manner (IC₅₀, ~34 nM for RBL-2H3 cells; ~52 nM for BMMCs) without any cytotoxicity. It also suppressed the secretion of inflammatory cytokines IL-4 and TNF-α by antigen stimulation. Furthermore, dasatinib inhibited MC-mediated passive cutaneous anaphylaxis (PCA) in mice (ED₅₀, ~29 mg/kg). Notably, dasatinib significantly suppressed the degranulation of MCs in the ear tissue. As the mechanism of its effect, dasatinib inhibited the activation of Syk and Syk-mediated downstream signaling proteins, LAT, PLCγ1, and three typical MAP kinases (Erk1/2, JNK, and p38), which are essential for the activation of MCs. Interestingly, in vitro tyrosine kinase assay, dasatinib directly inhibited the activities of Lyn and Fyn, the upstream tyrosine kinases of Syk in MCs. Taken together, dasatinib suppresses MCs and PCA in vitro and in vivo through the inhibition of Lyn and Fyn Src-family kinases. Therefore, we suggest the possibility of repositioning the anti-cancer drug dasatinib as a treatment for various MC-mediated type I hypersensitive diseases.